e-Edition
Obituaries
Special Sections
Special Occasions
Contact

Subscribe
Paywall Login
Login to Comment
Register

December 11th, 2017

jobs

homes

Home
News
Sports
Business
Entertainment
Classifieds
Commentary

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

46.15 -1.02 (-2.16%)

Streaming Delayed Price Updated: 11:54 AM EDT, Aug 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Hims & Hers’ Revenue Beat Came With a Profitability Problem ↗

Today 9:45 EDT

Hims & Hers topped Q2 revenue estimates and raised guidance, but missed EPS forecasts, posted a wider net loss, and faces an FTC lawsuit, leaving Wall Street cautious with a Hold rating.

Via MarketBeat

Topics Earnings Lawsuit

Novo Nordisk Stock: Buy or Sell? ↗

August 11, 2026

Sales of weight loss treatments have been incredible for Novo Nordisk.

Via The Motley Fool

Better Buy: Eli Lilly vs. Novo Nordisk ↗

August 11, 2026

Novo Nordisk is playing catch-up in the GLP-1 race.

Via The Motley Fool

Why Eli Lilly Topped the Market Today ↗

August 10, 2026

One of its more popular products just got the green light from a major national regulator.

Via The Motley Fool

Novo Nordisk A/S Q2 Earnings Call Highlights ↗

August 08, 2026

Novo Nordisk A/S (NYSE:NVO) reported second-quarter adjusted sales growth of 7% at constant exchange rates, supported by GLP-1 volume growth across its obesity and diabetes franchises, while lower...

Via MarketBeat

Topics Earnings

Eli Lilly's Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official -- and Novo Nordisk Has a Problem ↗

August 07, 2026

Can anyone take the top spot away from Eli Lilly in the anti-obesity area?

Via The Motley Fool

Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy and Eli Lilly's Zepbound ↗

August 07, 2026

Berobenatide is one of the keys to Pfizer's future.

Via The Motley Fool

Why Is Everyone Talking About Novo Nordisk? ↗

August 06, 2026

The drugmaker continues to face headwinds.

Via The Motley Fool

The FTC Is Suing Hims & Hers Health—Here's Why Investors Shouldn't Panic ↗

August 05, 2026

Hims & Hers Health shares have rallied despite an FTC lawsuit over data sharing and billing practices, as weight-loss drug partnerships and Wall Street's cautious Hold rating shape the stock's outlook...

Via MarketBeat

Topics Lawsuit

Bearish Pressure Is Building Around These 3 Stocks ↗

August 03, 2026

Hims & Hers Health and QXO face heavy short interest amid dilution and loss concerns, while KLA has slid nearly 40% since June as AI-driven chip spending fears grip semiconductor stocks.

Via MarketBeat

Topics Artificial Intelligence

Novo Nordisk Shares Plunge After a Key Trial Fails. Should Investors Buy the Dip? ↗

July 31, 2026

With the stock near a 5-year low, is it worth a look?

Via The Motley Fool

Eli Lilly Stock Has Skyrocketed. Novo Nordisk Has Crashed. 1 Number Explains Why They're Not Even Close Anymore. ↗

July 31, 2026

The global market for obesity drugs is soaring, yet Lilly has a dominant market share.

Via The Motley Fool

3 Beaten-Down Stocks With GLP-1 Exposure to Buy and Hold ↗

July 29, 2026

They may profit from the rapidly growing GLP-1 market in very different ways.

Via The Motley Fool

Watch Out, Eli Lilly and Novo Nordisk: Amgen's Monthly Weight Loss Drug Has 6 Phase 3 Trials Running -- and It's Coming for Your Patients ↗

July 29, 2026

Will this pharma company become a new leader in the weight loss market?

Via The Motley Fool

Where Will Novo Nordisk Stock Be in 3 Years? ↗

July 28, 2026

Trailing a powerful competitor, Novo Nordisk could stay firmly in second place for a good while.

Via The Motley Fool

Why Is Novo Nordisk Suing Eli Lilly, and What Does it Mean for Investors? ↗

July 24, 2026

Novo Nordisk is accusing Eli Lilly of deceptive advertising about GLP-1 drugs.

Via The Motley Fool

Topics Lawsuit

2 Top Growth Stocks to Buy Right Now Without Any Hesitation ↗

July 24, 2026

There are plenty of reasons to love these companies.

Via The Motley Fool

3 Absurdly Cheap Dividend Stocks to Buy With $1,000 Right Now ↗

July 23, 2026

With yields like this, these undervalued tickers aren't apt to remain this cheap forever.

Via The Motley Fool

Topics Lawsuit

"Deceptive Advertising!" Claims Novo Nordisk in Explosive New GLP-1 Lawsuit Against Eli Lilly. Here's What That Means for Both Stocks. ↗

July 21, 2026

Novo Nordisk is also demanding that Eli Lilly pull its ads and pay damages.

Via The Motley Fool

Topics Lawsuit

Novo Nordisk's Dividend Story Is Changing -- Here's What Investors Are Missing ↗

July 21, 2026

Novo Nordisk is offering an attractive 3.5% yield backed by a business where volume is the new focus.

Via The Motley Fool

Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market? ↗

July 20, 2026

It is definitely a strong contender.

Via The Motley Fool

Topics Intellectual Property

Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1 ↗

July 18, 2026

Viking's latest program seeks to push the envelope in weight loss efficacy.

Via The Motley Fool

The Most Overlooked Reason Eli Lilly Stock Keeps Surging -- and It Has Nothing to Do With Weight Loss ↗

July 17, 2026

There's a good reason why investors are focused on Eli Lilly's GLP-1 business, but there's more going on at the company.

Via The Motley Fool

Topics Intellectual Property

Wegovy Pill Just Changed the GLP-1 Market. Here's Why Eli Lilly Stock Could Still Win ↗

July 17, 2026

Novo Nordisk is finally getting one up on its biggest rival.

Via The Motley Fool

3 High-Yield Dividend Stocks to Buy and Hold ↗

July 17, 2026

All three can be bought on the dip.

Via The Motley Fool

Topics Intellectual Property

This GLP-1 Stock Could Double by 2030. Here's Why ↗

July 16, 2026

Investors need to ask tough questions before initiating a position in this biotech company.

Via The Motley Fool

2 Beaten-Down GLP-1 Stocks to Buy on the Dip ↗

July 15, 2026

Don't wait until clinical milestones send their share prices soaring.

Via The Motley Fool

Is This Disturbing Trend Bad News for Eli Lilly in the Billion-Dollar Obesity Drug Market? ↗

July 14, 2026

Eyes are on the rollout of Lilly's new weight loss pill.

Via The Motley Fool

3 Dividend Stocks That Are No-Brainer Buys Heading Into the Second Half of 2026 ↗

July 11, 2026

This is the list for you if you are looking for dividend stocks with attractive yields and well-supported dividends.

Via The Motley Fool

Should You Buy Eli Lilly Stock? Here's My Honest Take. ↗

July 11, 2026

There are good reasons to invest in Lilly and to hold off.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

More ways to get to us

Facebook

Twitter

YouTube

ePaper Login
Subscribe
Subscription Services
Archive

About Us

The Lethbridge Herald
Other Publications
Food For Thought

Contact
Careers

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

Advertising
Terms and Conditions & Privacy Policy